Turning Point Brands Announces Fourth Quarter and Full Year 2022 Results
Turning Point Brands (TPB) reported FY 2022 financial results, with total net sales declining 6.8% to $415 million. Q4 2022 saw a 1.8% decrease in consolidated net sales to $103.4 million, influenced by an 11.1% drop in NewGen net sales. Combined Zig-Zag and Stoker’s Products net sales rose 1.6%. Gross profit decreased 5.6% to $205.5 million, while net income fell to $11.6 million, impacted by $41.1 million in non-cash asset impairments. The company aims for adjusted EBITDA of $88 to $94 million in 2023. CEO Graham Purdy emphasized a strategic shift towards organic growth initiatives.
- Zig-Zag and Stoker’s Products net sales showed resilience, with the former increasing 1.6% and the latter 2.6% in Q4.
- Despite financial challenges, the company maintained a strong liquidity position with $127.8 million.
- Management's focus on strategic initiatives and organic growth is a positive forward-looking approach.
- Total net sales decreased 6.8% in FY 2022, indicating a concerning trend.
- NewGen segment sales plummeted 35.2% for FY 2022, significantly affecting overall performance.
- Net income saw a dramatic decline of $40.4 million due to asset impairments.
-
Q4 2022 vs. Q4 2021
-
Total consolidated net sales decreased
1.8% to$103.4 million -
Combined net sales for Zig-Zag and Stoker’s Products increased
1.6% (increased0.9% and2.6% , respectively) -
NewGen net sales declined by
11.1%
-
Combined net sales for Zig-Zag and Stoker’s Products increased
-
Gross profit decreased
1.5% to$49.6 million -
Net income decreased
to $($27.8 million $16.3) million primarily due to non-cash asset impairments$34.8 million -
Adjusted net income decreased
to$0.2 million $13.2 million -
Adjusted EBITDA decreased
2.9% to (see Schedule A for a reconciliation to net income)$23.1 million -
Diluted EPS of
and Adjusted Diluted EPS of$(0.93) compared to$0.69 and$0.57 in the same period one year ago, respectively (see Schedule B for a reconciliation to Diluted EPS)$0.66
FY 2022 vs. FY 2021
-
Total consolidated net sales decreased
6.8% to$415.0 million -
Combined net sales for Zig-Zag and Stoker’s Products increased
6.8% (increased7.9% and5.3% , respectively) -
NewGen net sales declined by
35.2%
-
Combined net sales for Zig-Zag and Stoker’s Products increased
-
Gross profit decreased
5.6% to$205.5 million -
Net income decreased
to$40.4 million due in part to$11.6 million non-cash asset impairments$41.1 million -
Adjusted net income decreased
to$7.4 million $56.2 million -
Adjusted EBITDA decreased
9.7% to (see Schedule A for a reconciliation to net income)$97.6 million -
Diluted EPS of
and Adjusted Diluted EPS of$0.64 as compared to$2.83 and$2.52 in the same period one year ago, respectively (see Schedule B for a reconciliation to Diluted EPS)$3.03
Zig-Zag Products Segment (
For the fourth quarter, Zig-Zag Products net sales increased
For the quarter, the Zig-Zag Products segment gross profit decreased
For the full year, net sales of Zig-Zag Products increased
For the full year, Zig-Zag Products segment gross profit increased
“Zig-Zag papers demonstrated solid share growth for the year while we continue to build our presence in the alternative channel,” said Purdy. “Furthermore, we remain excited about our continued roll-out of CLIPPER lighters in the
Stoker’s Products Segment (
For the fourth quarter, Stoker’s Products net sales increased
For the quarter, the Stoker’s Products segment gross profit increased
For the full year, net sales of Stoker’s Products increased
For the full year, the Stoker’s Products segment gross profit increased
“Stoker’s saw strong market share gains in both the MST and loose-leaf chewing tobacco categories during the quarter,” continued Purdy. “Stoker’s strong value proposition continues to resonate with consumers in the current inflationary environment that has challenged their budgets.”
NewGen Products Segment (
For the fourth quarter, NewGen Products net sales decreased
For the quarter, NewGen Products segment gross profit decreased
For the full year, net sales of NewGen Products decreased
“The regulatory environment for NewGen remains dynamic given the uncertainty over the outcome of the PMTA process and the potential for additional state and federal regulations,” concluded Purdy.
Recent Events
Creative Distribution Solutions
On
Performance Measures in the Fourth Quarter
Fourth quarter consolidated selling, general and administrative (“SG&A”) expenses were
The fourth quarter SG&A included the following notable items:
-
of ERP / CRM duplicative system costs compared to none in the previous year$0.3 million -
of stock options, restricted stock and incentive expense compared to$1.2 million in the year-ago period$1.5 million -
of FDA PMTA-related expenses compared to$0.3 million in the year-ago period$0.7 million -
of transaction expenses as compared to$0.0 million in the year-ago period$0.2 million -
of restructuring costs as compared to$1.8 million in the year-ago period$0.9 million
Total gross debt as of
During the quarter, the Company spent
The Company recorded impairment charges of
2023 Outlook
At this time, the Company expects full-year 2023 adjusted EBITDA to be
Earnings Conference Call
As previously disclosed, a conference call with the investment community to review TPB’s financial results has been scheduled for
Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles in
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may generally be identified by the use of words such as "anticipate," "believe," "expect," "intend," "plan" and "will" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. As a result, these statements are not guarantees of future performance and actual events may differ materially from those expressed in or suggested by the forward-looking statements. Any forward-looking statement made by TPB in this press release, its reports filed with the
Financial Statements Follow:
Consolidated Statements of Income | |||||||
(dollars in thousands except share data) | |||||||
(unaudited) | |||||||
Three Months Ended |
|||||||
|
|||||||
|
2022 |
|
|
2021 |
|
||
Net sales | $ |
103,392 |
|
$ |
105,283 |
|
|
Cost of sales |
|
53,829 |
|
|
54,952 |
|
|
Gross profit |
|
49,563 |
|
|
50,331 |
|
|
Selling, general, and administrative expenses |
|
31,245 |
|
|
31,613 |
|
|
Operating income |
|
18,318 |
|
|
18,718 |
|
|
Interest expense, net |
|
4,382 |
|
|
5,094 |
|
|
Investment loss |
|
7,229 |
|
|
6,965 |
|
|
|
27,566 |
|
|
- |
|
||
Gain on extinguishment of debt |
|
(885 |
) |
|
(7,485 |
) |
|
Income (loss) before income taxes |
|
(19,974 |
) |
|
14,144 |
|
|
Income tax (benefit) expense |
|
(3,857 |
) |
|
2,889 |
|
|
Consolidated net income (loss) |
|
(16,117 |
) |
|
11,255 |
|
|
Net income (loss) attributable to non-controlling interest |
|
200 |
|
|
(199 |
) |
|
Net income (loss) attributable to |
$ |
(16,317 |
) |
$ |
11,454 |
|
|
Basic income (loss) per common share: | |||||||
Net income (loss) attributable to |
$ |
(0.93 |
) |
$ |
0.61 |
|
|
Diluted income (loss) per common share: | |||||||
Net income (loss) attributable to |
$ |
(0.93 |
) |
$ |
0.57 |
|
|
Weighted average common shares outstanding: | |||||||
Basic |
|
17,530,278 |
|
|
18,707,286 |
|
|
Diluted |
|
17,530,278 |
|
|
22,153,988 |
|
|
Supplemental disclosures of statement of income information: | |||||||
Excise tax expense | $ |
5,771 |
|
$ |
6,212 |
|
|
FDA fees | $ |
158 |
|
$ |
166 |
|
|
Consolidated Statements of Income | |||||||
(dollars in thousands except share data) | |||||||
(unaudited) | |||||||
For the year ended |
|||||||
|
|||||||
|
2022 |
|
|
2021 |
|
||
Net sales | $ |
415,013 |
|
$ |
445,471 |
|
|
Cost of sales |
|
209,475 |
|
|
227,637 |
|
|
Gross profit |
|
205,538 |
|
|
217,834 |
|
|
Selling, general, and administrative expenses |
|
130,024 |
|
|
127,513 |
|
|
Operating income |
|
75,514 |
|
|
90,321 |
|
|
Interest expense, net |
|
19,524 |
|
|
20,500 |
|
|
Investment loss |
|
13,303 |
|
|
6,673 |
|
|
|
27,566 |
|
|
- |
|
||
Gain on extinguishment of debt, net |
|
(885 |
) |
|
(2,154 |
) |
|
Income before income taxes |
|
16,006 |
|
|
65,302 |
|
|
Income tax expense |
|
4,849 |
|
|
14,040 |
|
|
Consolidated net income |
|
11,157 |
|
|
51,262 |
|
|
Net loss attributable to non-controlling interest |
|
(484 |
) |
|
(797 |
) |
|
Net income attributable to |
$ |
11,641 |
|
$ |
52,059 |
|
|
Basic income per common share: | |||||||
Net income attributable to |
$ |
0.65 |
|
$ |
2.75 |
|
|
Diluted income per common share: | |||||||
Net income attributable to |
$ |
0.64 |
|
$ |
2.52 |
|
|
Weighted average common shares outstanding: | |||||||
Basic |
|
17,899,794 |
|
|
18,917,570 |
|
|
Diluted |
|
18,055,015 |
|
|
22,381,994 |
|
|
Supplemental disclosures of statement of income information: | |||||||
Excise tax expense | $ |
23,274 |
|
$ |
27,353 |
|
|
FDA fees | $ |
623 |
|
$ |
679 |
|
Consolidated Balance Sheets | |||||||
(dollars in thousands except share data) | |||||||
(unaudited) | |||||||
ASSETS |
|
2022 |
|
|
2021 |
|
|
Current assets: | |||||||
Cash | $ |
106,403 |
|
$ |
128,320 |
|
|
Accounts receivable, net of allowances of |
|
8,377 |
|
|
6,496 |
|
|
Inventories |
|
119,915 |
|
|
87,607 |
|
|
Other current assets |
|
21,800 |
|
|
26,746 |
|
|
Total current assets |
|
256,495 |
|
|
249,169 |
|
|
Property, plant, and equipment, net |
|
22,788 |
|
|
18,650 |
|
|
Deferred income taxes |
|
9,602 |
|
|
1,363 |
|
|
Right of use assets |
|
12,465 |
|
|
15,053 |
|
|
Deferred financing costs, net |
|
282 |
|
|
388 |
|
|
|
136,253 |
|
|
162,333 |
|
||
Other intangible assets, net |
|
83,592 |
|
|
87,485 |
|
|
Master Settlement Agreement (MSA) escrow deposits |
|
27,980 |
|
|
31,720 |
|
|
Other assets |
|
22,649 |
|
|
35,399 |
|
|
Total assets | $ |
572,106 |
|
$ |
601,560 |
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ |
8,355 |
|
$ |
7,361 |
|
|
Accrued liabilities |
|
33,001 |
|
|
32,937 |
|
|
Current portion of long-term debt |
|
- |
|
|
- |
|
|
Other current liabilities |
|
20 |
|
|
38 |
|
|
Total current liabilities |
|
41,376 |
|
|
40,336 |
|
|
Notes payable and long-term debt |
|
406,757 |
|
|
414,172 |
|
|
Lease liabilities |
|
10,593 |
|
|
13,336 |
|
|
Total liabilities |
|
458,726 |
|
|
467,844 |
|
|
Commitments and contingencies | |||||||
Stockholders' equity: | |||||||
Preferred stock; |
|
- |
|
|
- |
|
|
Common stock, voting, |
|
198 |
|
|
197 |
|
|
Common stock, nonvoting, |
|||||||
issued and outstanding shares -0- |
|
- |
|
|
- |
|
|
Additional paid-in capital |
|
113,242 |
|
|
108,811 |
|
|
Cost of repurchased common stock (2,316,460 shares at |
|
(78,093 |
) |
|
(48,869 |
) |
|
Accumulated other comprehensive loss |
|
(2,393 |
) |
|
(195 |
) |
|
Accumulated earnings |
|
78,691 |
|
|
71,460 |
|
|
Non-controlling interest |
|
1,735 |
|
|
2,312 |
|
|
Total stockholders' equity |
|
113,380 |
|
|
133,716 |
|
|
Total liabilities and stockholders' equity | $ |
572,106 |
|
$ |
601,560 |
|
|
Consolidated Statements of Cash Flows | |||||||
(dollars in thousands) | |||||||
(unaudited) | |||||||
For the Year Ended |
|||||||
|
|||||||
|
2022 |
|
|
2021 |
|
||
Cash flows from operating activities: | |||||||
Consolidated net income | $ |
11,157 |
|
$ |
51,262 |
|
|
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||
Gain on extinguishment of debt |
|
(885 |
) |
|
(2,154 |
) |
|
Gain on disposal of property, plant, and equipment |
|
(9 |
) |
|
(54 |
) |
|
Loss on goodwill impairment |
|
25,585 |
|
|
- |
|
|
Loss on intangible asset impairment |
|
1,982 |
|
|
- |
|
|
Loss on investments |
|
13,570 |
|
|
7,100 |
|
|
Depreciation expense |
|
3,388 |
|
|
3,105 |
|
|
Amortization of other intangible assets |
|
1,911 |
|
|
1,907 |
|
|
Amortization of deferred financing costs |
|
2,576 |
|
|
2,541 |
|
|
Deferred income taxes |
|
(7,665 |
) |
|
(1,485 |
) |
|
Stock compensation expense |
|
5,273 |
|
|
7,557 |
|
|
Noncash lease income |
|
(29 |
) |
|
(167 |
) |
|
Gain on MSA escrow deposits |
|
(54 |
) |
|
(255 |
) |
|
Changes in operating assets and liabilities: | |||||||
Accounts receivable |
|
(2,103 |
) |
|
3,317 |
|
|
Inventories |
|
(32,653 |
) |
|
(9 |
) |
|
Other current assets |
|
5,739 |
|
|
(134 |
) |
|
Other assets |
|
420 |
|
|
996 |
|
|
Accounts payable |
|
1,240 |
|
|
(2,367 |
) |
|
Accrued liabilities and other |
|
830 |
|
|
(2,943 |
) |
|
Net cash provided by operating activities |
|
30,273 |
|
|
68,217 |
|
|
Cash flows from investing activities: | |||||||
Capital expenditures | $ |
(7,685 |
) |
$ |
(6,156 |
) |
|
Acquisitions, net of cash acquired |
|
- |
|
|
(16,416 |
) |
|
Payments for investments |
|
(1,000 |
) |
|
(16,657 |
) |
|
Restricted cash, MSA escrow deposits |
|
(10,170 |
) |
|
(19,664 |
) |
|
Proceeds on the sale of property, plant and equipment |
|
62 |
|
|
54 |
|
|
Net cash used in investing activities |
|
(18,793 |
) |
|
(58,839 |
) |
|
Consolidated Statements of Cash Flows (Cont.) | |||||||
(dollars in thousands) | |||||||
(unaudited) | |||||||
For the Year Ended |
|||||||
|
|||||||
|
2022 |
|
|
2021 |
|
||
Cash flows from financing activities: | |||||||
Proceeds from Senior Notes | $ |
- |
|
$ |
250,000 |
|
|
Payments of 2018 first lien term loan |
|
- |
|
|
(130,000 |
) |
|
Settlement of interest rate swaps |
|
- |
|
|
(3,573 |
) |
|
Payments of Convertible Senior Notes |
|
(9,000 |
) |
|
- |
|
|
Proceeds from call options |
|
51 |
|
|
- |
|
|
Payment of promissory note |
|
- |
|
|
(9,625 |
) |
|
Payment of dividends |
|
(4,250 |
) |
|
(4,096 |
) |
|
Payments of financing costs |
|
- |
|
|
(6,921 |
) |
|
Exercise of options |
|
504 |
|
|
2,071 |
|
|
Redemption of options |
|
(155 |
) |
|
(2,111 |
) |
|
Redemption of restricted stock |
|
(1,229 |
) |
|
- |
|
|
Common stock repurchased |
|
(29,224 |
) |
|
(38,678 |
) |
|
Net cash provided by (used in) financing activities | $ |
(43,303 |
) |
$ |
57,067 |
|
|
Net increase (decrease) in cash | $ |
(31,823 |
) |
$ |
66,445 |
|
|
Effect of foreign currency translation on cash | $ |
(320 |
) |
$ |
191 |
|
|
Cash, beginning of period: | |||||||
Unrestricted | $ |
128,320 |
|
$ |
41,765 |
|
|
Restricted |
|
15,155 |
|
|
35,074 |
|
|
Total cash at beginning of period | $ |
143,475 |
|
$ |
76,839 |
|
|
Unrestricted | $ |
106,403 |
|
$ |
128,320 |
|
|
Restricted |
|
4,929 |
|
|
15,155 |
|
|
Total cash at end of period | $ |
111,332 |
|
$ |
143,475 |
|
Non-GAAP Financial Measures
To supplement our financial information presented in accordance with generally accepted accounting principles in
We define “EBITDA” as net income before interest expense, loss on extinguishment of debt, provision for income taxes, depreciation and amortization. We define “Adjusted EBITDA” as net income before interest expense, loss on extinguishment of debt, provision for income taxes, depreciation, amortization, other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Net Income” as net income excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Diluted EPS” as diluted earnings per share excluding items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Gross Profit: as gross profit excluding other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance. We define “Adjusted Operating Income (Loss)” as operating income (loss) excluding other non-cash items and other items that we do not consider ordinary course in our evaluation of ongoing operating performance.
Non-
In accordance with
Schedule A | |||||||
Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA | |||||||
(dollars in thousands) | |||||||
(unaudited) | |||||||
Three Months Ended |
|||||||
|
|||||||
|
2022 |
|
|
2021 |
|
||
Net income (loss) attributable to |
$ |
(16,317 |
) |
$ |
11,454 |
|
|
Add: | |||||||
Interest expense, net |
|
4,382 |
|
|
5,094 |
|
|
Gain on extinguishment of debt |
|
(885 |
) |
|
(7,485 |
) |
|
Income tax (benefit) expense |
|
(3,857 |
) |
|
2,889 |
|
|
Depreciation expense |
|
777 |
|
|
792 |
|
|
Amortization expense |
|
538 |
|
|
476 |
|
|
EBITDA | $ |
(15,362 |
) |
$ |
13,220 |
|
|
Components of Adjusted EBITDA | |||||||
Corporate restructuring (a) |
|
1,825 |
|
|
1,026 |
|
|
ERP/CRM (b) |
|
336 |
|
|
- |
|
|
Stock options, restricted stock, and incentives expense (c) |
|
1,170 |
|
|
1,542 |
|
|
Transactional expenses (d) |
|
12 |
|
|
190 |
|
|
FDA PMTA (e) |
|
289 |
|
|
708 |
|
|
Non-cash asset impairment (f) |
|
34,836 |
|
|
7,100 |
|
|
Adjusted EBITDA | $ |
23,106 |
|
$ |
23,786 |
|
|
(a) Represents costs associated with corporate and vape restructuring, including severance. | |||||||
(b) Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses. | |||||||
(c) Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units. | |||||||
(d) Represents the fees incurred for transaction expenses. | |||||||
(e) Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA"). | |||||||
(f) Represents impairment of goodwill, intangible and investment assets. |
Schedule A | |||||||
Reconciliation of GAAP Net Income to Adjusted EBITDA | |||||||
(dollars in thousands) | |||||||
(unaudited) | |||||||
For the Year Ended |
|||||||
|
|||||||
|
2022 |
|
|
2021 |
|
||
Net income attributable to |
$ |
11,641 |
|
$ |
52,059 |
|
|
Add: | |||||||
Interest expense, net |
|
19,524 |
|
|
20,500 |
|
|
Gain on extinguishment of debt |
|
(885 |
) |
|
(2,154 |
) |
|
Income tax expense |
|
4,849 |
|
|
14,040 |
|
|
Depreciation expense |
|
3,388 |
|
|
3,105 |
|
|
Amortization expense |
|
1,911 |
|
|
1,907 |
|
|
EBITDA | $ |
40,428 |
|
$ |
89,457 |
|
|
Components of Adjusted EBITDA | |||||||
Corporate restructuring (a) |
|
3,444 |
|
|
1,026 |
|
|
ERP/CRM (b) |
|
1,962 |
|
|
- |
|
|
Stock options, restricted stock, and incentives expense (c) |
|
5,273 |
|
|
7,557 |
|
|
Transactional expenses (d) |
|
801 |
|
|
1,267 |
|
|
FDA PMTA (e) |
|
4,554 |
|
|
1,668 |
|
|
Non-cash asset impairment (f) |
|
41,136 |
|
|
7,100 |
|
|
Adjusted EBITDA | $ |
97,598 |
|
$ |
108,075 |
|
|
(a) Represents costs associated with corporate and vape restructuring, including severance. | |||||||
(b) Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses. | |||||||
(c) Represents non-cash stock options, restricted stock, incentives expense and Solace performance stock units. | |||||||
(d) Represents the fees incurred for transaction expenses. | |||||||
(e) Represents costs associated with applications related to FDA premarket tobacco product application ("PMTA"). | |||||||
(f) Represents impairment of goodwill, intangible and investment assets. |
Schedule B | |||||||||||||||
Reconciliation of GAAP Net Income to Adjusted Net Income and Diluted EPS to Adjusted Diluted EPS | |||||||||||||||
(dollars in thousands except share data) | |||||||||||||||
(unaudited) | |||||||||||||||
Three Months Ended | Three Months Ended | ||||||||||||||
Net Income | Diluted EPS | Net Income | Diluted EPS | ||||||||||||
GAAP | $ |
(16,317 |
) |
$ |
(0.93 |
) |
$ |
11,454 |
|
$ |
0.57 |
|
|||
Anti-dilutive impact (a) |
|
- |
|
|
0.20 |
|
|
- |
|
|
- |
|
|||
Gain on extinguishment of debt (b) |
|
(714 |
) |
|
(0.03 |
) |
|
(5,956 |
) |
|
(0.27 |
) |
|||
Corporate restructuring (c) |
|
1,473 |
|
|
0.07 |
|
|
816 |
|
|
0.04 |
|
|||
ERP/CRM (d) |
|
271 |
|
|
0.01 |
|
|
- |
|
|
- |
|
|||
Stock options, restricted stock, and incentives expense (e) |
|
944 |
|
|
0.05 |
|
|
1,227 |
|
|
0.06 |
|
|||
Transactional expenses (f) |
|
10 |
|
|
0.00 |
|
|
151 |
|
|
0.01 |
|
|||
FDA PMTA (g) |
|
233 |
|
|
0.01 |
|
|
563 |
|
|
0.03 |
|
|||
Non-cash asset impairment (h) |
|
28,109 |
|
|
1.35 |
|
|
5,650 |
|
|
0.26 |
|
|||
Impact of quarterly tax items to effective tax rate (i) |
|
(804 |
) |
|
(0.04 |
) |
|
(540 |
) |
|
(0.02 |
) |
|||
Adjusted (j) | $ |
13,205 |
|
$ |
0.69 |
|
$ |
13,366 |
|
$ |
0.66 |
|
|||
Total may not foot due to rounding | |||||||||||||||
(a) Represents dilution of options and debt conversion that is anti-dilutive and not included for GAAP. | |||||||||||||||
(b) Represents gain on extinguishment of debt tax effected at the quarterly tax rate. | |||||||||||||||
(c) Represents costs associated with corporate restructuring, including severance tax effected at the quarterly tax rate. | |||||||||||||||
(d) Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses tax effected at the quarterly tax rate. | |||||||||||||||
(e) Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs tax effected at the quarterly tax rate. | |||||||||||||||
(f) Represents the fees incurred for transaction expenses tax effected at the quarterly tax rate. | |||||||||||||||
(g) Represents costs associated with applications related to the FDA PMTA tax effected at the quarterly tax rate. | |||||||||||||||
(h) Represents impairment of goodwill, intangible and investment assets tax effected at the quarterly tax rate. | |||||||||||||||
(i) Represents adjustment from quarterly tax rate to annual projected tax rate of |
|||||||||||||||
(j) Diluted shares outstanding includes the full 3.2 million share dilution of debt conversion without a 1.1 million share offsetting impact from capped call transactions. |
Schedule B | |||||||||||||||
Reconciliation of GAAP Net Income to Adjusted Net Income and Diluted EPS to Adjusted Diluted EPS | |||||||||||||||
(dollars in thousands except share data) | |||||||||||||||
(unaudited) | |||||||||||||||
For the Year Ended | For the Year Ended | ||||||||||||||
Net Income | Diluted EPS | Net Income | Diluted EPS | ||||||||||||
GAAP | $ |
11,641 |
|
$ |
0.64 |
|
$ |
52,059 |
|
$ |
2.52 |
|
|||
Anti-dilutive impact (a) |
|
- |
|
|
0.09 |
|
|
- |
|
|
- |
|
|||
Gain on extinguishment of debt (b) |
|
(617 |
) |
|
(0.03 |
) |
|
(1,691 |
) |
|
(0.08 |
) |
|||
Corporate restructuring (c) |
|
2,401 |
|
|
0.11 |
|
|
805 |
|
|
0.04 |
|
|||
ERP/CRM (d) |
|
1,368 |
|
|
0.06 |
|
|
- |
|
|
- |
|
|||
Stock options, restricted stock, and incentives expense (e) |
|
3,676 |
|
|
0.17 |
|
|
5,932 |
|
|
0.27 |
|
|||
Transactional expenses (f) |
|
558 |
|
|
0.03 |
|
|
995 |
|
|
0.04 |
|
|||
FDA PMTA (g) |
|
3,174 |
|
|
0.15 |
|
|
1,309 |
|
|
0.06 |
|
|||
Non-cash asset impairment (h) |
|
28,674 |
|
|
1.35 |
|
|
5,573 |
|
|
0.25 |
|
|||
Impact of quarterly tax items to effective tax rate (i) |
|
5,309 |
|
|
0.25 |
|
|
(1,432 |
) |
|
(0.06 |
) |
|||
Adjusted (j) | $ |
56,183 |
|
$ |
2.83 |
|
$ |
63,551 |
|
$ |
3.03 |
|
|||
Total may not foot due to rounding | |||||||||||||||
(a) Represents dilution of debt conversion that is anti-dilutive and not included for GAAP. | |||||||||||||||
(b) Represents gain on extinguishment of debt tax effected at the quarterly tax rate. | |||||||||||||||
(c) Represents costs associated with corporate restructuring, including severance tax effected at the quarterly tax rate. | |||||||||||||||
(d) Represents cost associated with scoping and mobilization of new ERP and CRM systems and cost of duplicative ERP licenses tax effected at the quarterly tax rate. | |||||||||||||||
(e) Represents non-cash stock options, restricted stock, incentives expense and Solace PRSUs tax effected at the quarterly tax rate. | |||||||||||||||
(f) Represents the fees incurred for transaction expenses tax effected at the quarterly tax rate. | |||||||||||||||
(g) Represents costs associated with applications related to the FDA PMTA tax effected at the quarterly tax rate. | |||||||||||||||
(h) Represents impairment of goodwill, intangible and investment assets tax effected at the quarterly tax rate. | |||||||||||||||
(i) Represents adjustment from quarterly tax rate to annual projected tax rate of |
|||||||||||||||
(j) Diluted shares outstanding includes the full 3.2 million share dilution of debt conversion without a 1.1 million share offsetting impact from capped call transactions. |
Schedule C | ||||||||||||||||||||||||
Reconciliation of GAAP Gross Profit to Adjusted Gross Profit and GAAP Operating Income to Adjusted Operating Income (Loss) | ||||||||||||||||||||||||
(dollars in thousands) | ||||||||||||||||||||||||
(unaudited) | ||||||||||||||||||||||||
Consolidated | Zig-Zag | Stoker's | NewGen | |||||||||||||||||||||
4th Quarter | 4th Quarter | 4th Quarter | 4th Quarter | 4th Quarter | 4th Quarter | 4th Quarter | 4th Quarter | |||||||||||||||||
2022 |
2021 |
2022 |
2021 |
2022 |
2021 |
2022 |
|
2021 |
|
|||||||||||||||
Net sales | $ |
103,392 |
$ |
105,283 |
$ |
46,444 |
$ |
46,051 |
$ |
32,010 |
$ |
31,184 |
$ |
24,938 |
$ |
28,048 |
|
|||||||
Gross profit | $ |
49,563 |
$ |
50,331 |
$ |
25,768 |
$ |
26,397 |
$ |
17,210 |
$ |
16,942 |
$ |
6,585 |
$ |
6,992 |
|
|||||||
Adjustments: | ||||||||||||||||||||||||
Corporate and vapor restructuring |
|
- |
|
90 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
90 |
|
|||||||
Adjusted gross profit | $ |
49,563 |
$ |
50,421 |
$ |
25,768 |
$ |
26,397 |
$ |
17,210 |
$ |
16,942 |
$ |
6,585 |
$ |
7,082 |
|
|||||||
Operating income (loss) | $ |
18,318 |
$ |
18,718 |
$ |
17,362 |
$ |
19,212 |
$ |
12,794 |
$ |
12,687 |
$ |
134 |
$ |
(3,427 |
) |
|||||||
Adjustments: | ||||||||||||||||||||||||
Transaction costs |
|
12 |
|
190 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|
|||||||
FDA PMTA |
|
289 |
|
708 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|
|||||||
Corporate and vapor restructuring |
|
1,825 |
|
1,026 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
1,026 |
|
|||||||
Adjusted operating income (loss) | $ |
20,444 |
$ |
20,642 |
$ |
17,362 |
$ |
19,212 |
$ |
12,794 |
$ |
12,687 |
$ |
134 |
$ |
(2,401 |
) |
|||||||
Schedule C | |||||||||||||||||||||||
Reconciliation of GAAP Gross Profit to Adjusted Gross Profit and GAAP Operating Income to Adjusted Operating Income | |||||||||||||||||||||||
(dollars in thousands) | |||||||||||||||||||||||
(unaudited) | |||||||||||||||||||||||
Consolidated | Zig-Zag | Stoker's | NewGen | ||||||||||||||||||||
YTD | YTD | YTD | YTD | YTD | YTD | YTD | YTD | ||||||||||||||||
2022 |
2021 |
2022 |
2021 |
2022 |
2021 |
2022 |
2021 |
||||||||||||||||
Net sales | $ |
415,013 |
$ |
445,471 |
$ |
190,403 |
$ |
176,491 |
$ |
130,826 |
$ |
124,280 |
$ |
93,784 |
$ |
144,700 |
|||||||
Gross profit | $ |
205,538 |
$ |
217,834 |
$ |
106,576 |
$ |
102,739 |
$ |
71,254 |
$ |
68,084 |
$ |
27,708 |
$ |
47,011 |
|||||||
Adjustments: | |||||||||||||||||||||||
Corporate and vapor restructuring |
|
- |
|
90 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
90 |
|||||||
Adjusted gross profit | $ |
205,538 |
$ |
217,924 |
$ |
106,576 |
$ |
102,739 |
$ |
71,254 |
$ |
68,084 |
$ |
27,708 |
$ |
47,101 |
|||||||
Operating income | $ |
75,514 |
$ |
90,321 |
$ |
73,342 |
$ |
77,109 |
$ |
51,929 |
$ |
52,073 |
$ |
1,506 |
$ |
2,263 |
|||||||
Adjustments: | |||||||||||||||||||||||
Transaction costs |
|
801 |
|
1,267 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|||||||
FDA PMTA |
|
4,554 |
|
1,668 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
- |
|||||||
Corporate and vapor restructuring |
|
3,444 |
|
1,026 |
|
- |
|
- |
|
- |
|
- |
|
- |
|
1,026 |
|||||||
Adjusted operating income | $ |
84,313 |
$ |
94,282 |
$ |
73,342 |
$ |
77,109 |
$ |
51,929 |
$ |
52,073 |
$ |
1,506 |
$ |
3,289 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20230224005079/en/
Investor Contacts
502.774.9238
ir@tpbi.com
Source:
FAQ
What were the total net sales for Turning Point Brands in FY 2022?
How did Zig-Zag and Stoker’s Products perform in Q4 2022?
What was the net income for TPB in FY 2022?
What are TPB's expected adjusted EBITDA figures for 2023?